A detailed history of Freestone Grove Partners LP transactions in Geron Corp stock. As of the latest transaction made, Freestone Grove Partners LP holds 44,853 shares of GERN stock, worth $113,926. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,853
Holding current value
$113,926
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$3.3 - $4.44 $148,014 - $199,147
44,853 New
44,853 $159 Million

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $960M
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.